Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:DVAXNYSE:EBSNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$21.45+0.4%$19.18$14.40▼$47.00$1.41B1.59880,926 shs256,171 shsDVAXDynavax Technologies$11.62+3.1%$12.74$9.74▼$14.63$1.42B1.262.19 million shs826,843 shsEBSEmergent BioSolutions$5.50+0.8%$5.49$1.82▼$15.10$299.07M2.142.65 million shs406,080 shsMNKDMannKind$4.85+2.4%$4.99$4.11▼$7.63$1.47B1.222.39 million shs609,741 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+9.15%+12.78%+7.18%-13.24%-41.16%DVAXDynavax Technologies+4.16%+7.95%-17.62%-12.91%+0.54%EBSEmergent BioSolutions-1.09%+19.56%+16.36%-50.42%+183.33%MNKDMannKind-0.21%+6.53%-5.96%-22.59%+11.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.9912 of 5 stars4.50.00.00.03.50.00.0DVAXDynavax Technologies4.1774 of 5 stars3.22.00.04.72.21.71.9EBSEmergent BioSolutions4.1453 of 5 stars3.51.00.04.62.32.51.3MNKDMannKind3.1476 of 5 stars3.62.00.00.03.70.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.90Moderate Buy$55.30157.81% UpsideDVAXDynavax Technologies 2.33Hold$20.5076.50% UpsideEBSEmergent BioSolutions 3.00Buy$14.33160.84% UpsideMNKDMannKind 3.22Buy$9.5697.37% UpsideCurrent Analyst Ratings BreakdownLatest EBS, MNKD, DVAX, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.004/17/2025DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$12.00 ➝ $10.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/1/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/21/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/20/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$46.003/4/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/3/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$42.00 ➝ $36.002/28/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.002/27/2025MNKDMannKindWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M202.84N/AN/A$9.08 per share2.36DVAXDynavax Technologies$277.25M5.13N/AN/A$4.81 per share2.41EBSEmergent BioSolutions$1.01B0.29$0.62 per share8.92$12.51 per share0.44MNKDMannKind$285.50M5.16N/AN/A($0.91) per share-5.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.45N/AN/AN/A-1,544.32%-19.75%-18.86%5/5/2025 (Estimated)DVAXDynavax Technologies-$6.39M$0.1864.5023.70N/A9.85%4.22%2.67%5/6/2025 (Estimated)EBSEmergent BioSolutions-$760.50M-$3.73N/A2.65N/A-18.55%-9.91%-3.31%4/29/2025 (Estimated)MNKDMannKind-$11.94M$0.1069.2121.07N/A8.07%-17.74%8.68%5/6/2025 (Estimated)Latest EBS, MNKD, DVAX, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MNKDMannKind$0.03N/AN/AN/A$75.86 millionN/A5/7/2025Q1 2025EBSEmergent BioSolutions$0.71N/AN/AN/A$218.50 millionN/A5/6/2025Q1 2025DVAXDynavax Technologies$0.03N/AN/AN/A$70.01 millionN/A5/5/2025Q1 2025CLDXCelldex Therapeutics-$0.75N/AN/AN/A$1.08 millionN/A3/3/2025Q4 2024EBSEmergent BioSolutions-$0.35$0.05+$0.40-$0.58$254.67 million$194.70 million2/27/2025Q4 2024CLDXCelldex Therapeutics-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million2/26/2025Q4 2024MNKDMannKind$0.03$0.03N/A$0.03$74.99 million$76.78 million2/20/2025Q4 2024DVAXDynavax Technologies$0.05$0.05N/A$0.05$72.70 million$72.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/AEBSEmergent BioSolutionsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27DVAXDynavax Technologies0.3313.2312.34EBSEmergent BioSolutions1.302.881.47MNKDMannKindN/A4.544.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/ADVAXDynavax Technologies96.96%EBSEmergent BioSolutions78.40%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%DVAXDynavax Technologies2.98%EBSEmergent BioSolutions1.20%MNKDMannKind3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableDVAXDynavax Technologies350122.41 million127.54 millionOptionableEBSEmergent BioSolutions2,42054.34 million53.53 millionOptionableMNKDMannKind400303.85 million267.51 millionOptionableEBS, MNKD, DVAX, and CLDX HeadlinesRecent News About These CompaniesRaymond James Financial Inc. Takes Position in MannKind Co. (NASDAQ:MNKD)April 29 at 3:42 AM | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Sold by Nitorum Capital L.P.April 28 at 6:46 AM | marketbeat.comOberweis Asset Management Inc. Has $6.23 Million Stock Holdings in MannKind Co. (NASDAQ:MNKD)April 27 at 6:18 AM | marketbeat.comMariner LLC Buys New Stake in MannKind Co. (NASDAQ:MNKD)April 27 at 4:03 AM | marketbeat.comInvesco Ltd. Lowers Stock Position in MannKind Co. (NASDAQ:MNKD)April 27 at 3:44 AM | marketbeat.comMarshall Wace LLP Buys 214,873 Shares of MannKind Co. (NASDAQ:MNKD)April 26 at 4:31 AM | marketbeat.comWalleye Capital LLC Lowers Stock Holdings in MannKind Co. (NASDAQ:MNKD)April 26 at 4:15 AM | marketbeat.comEversept Partners LP Has $5.86 Million Position in MannKind Co. (NASDAQ:MNKD)April 24, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 330,100 Shares of MannKind Co. (NASDAQ:MNKD)April 21, 2025 | marketbeat.comWells Fargo & Company MN Sells 209,520 Shares of MannKind Co. (NASDAQ:MNKD)April 21, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 190,563 Shares of MannKind Co. (NASDAQ:MNKD)April 20, 2025 | marketbeat.comMizuho Upgrades MannKind (NASDAQ:MNKD) to Strong-BuyApril 13, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by Vanguard Group Inc.April 12, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from BrokeragesApril 12, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Gap Down - Should You Sell?April 10, 2025 | marketbeat.comMannKind initiated with an Outperform at MizuhoApril 10, 2025 | markets.businessinsider.comMizuho starts MannKind with Outperform on positive Tyvaso checksApril 10, 2025 | markets.businessinsider.comExodusPoint Capital Management LP Has $2.86 Million Stake in MannKind Co. (NASDAQ:MNKD)April 9, 2025 | marketbeat.comPrudential Financial Inc. Lowers Position in MannKind Co. (NASDAQ:MNKD)April 9, 2025 | marketbeat.comMannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment OptionsApril 7, 2025 | globenewswire.comKLP Kapitalforvaltning AS Buys New Holdings in MannKind Co. (NASDAQ:MNKD)April 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEBS, MNKD, DVAX, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$21.45 +0.09 (+0.42%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Dynavax Technologies NASDAQ:DVAX$11.62 +0.35 (+3.06%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Emergent BioSolutions NYSE:EBS$5.50 +0.05 (+0.83%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.MannKind NASDAQ:MNKD$4.84 +0.12 (+2.43%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
